|
| related topics |
| {stock, price, share} |
| {stock, price, operating} |
| {product, liability, claim} |
| {interest, director, officer} |
| {personnel, key, retain} |
| {financial, litigation, operation} |
| {cost, operation, labor} |
| {product, market, service} |
|
|
Our operations have been devoted to marketing our products and we have not launched our products to a large number of customers, making it difficult to evaluate our future prospects and results of operations
We have only recently begun production of our product and may encounter manufacturing problems during the production process, which would adversely affect our results of operations and financial condition.
We currently lack liquidity and have limited revenues. We will need to raise additional capital, which will result in substantial dilution to existing stockholders.
Our Alenax products may contain unknown defects that could result in numerous adverse consequences
resulting in costly litigation or diverting management's attention and resources
We depend on our key personnel to manage our business effectively in a rapidly changing market. If we are unable to retain our key employees, our business, financial condition and results of operations could be harmed.
Our markets are highly competitive, and our failure to compete successfully would limit our ability to sell our products, attract and retain customers and grow our business.
Fluctuations in operating results could adversely affect the market price of our common stock.
All our officers and directors reside outside of the United States which could make it difficult to enforce potential civil liabilities and judgments.
Risks Related to Investment in Our Securities
There is a limited market for our common stock. Our common stock is thinly traded and, you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares.
Volatility in our common stock price may subject us to securities litigation.
The application of the penny stock rules could adversely affect the market price of our common stock and increase your transaction costs to sell those shares.
We do not expect to pay dividends for the foreseeable future, and we may never pay dividends. Investors seeking cash dividends should not purchase our common stock.
Full 10-K form ▸
|
|
| related documents |
| 1079028--11/26/2008--VARIAN_INC |
| 826253--6/15/2009--AURA_SYSTEMS_INC |
| 1372507--4/15/2009--RAVEN_BIOFUELS_INTERNATIONAL_CORP |
| 1292026--3/31/2008--Odimo_INC |
| 779956--4/30/2007--FASTFUNDS_FINANCIAL_CORP |
| 1292026--4/2/2007--Odimo_INC |
| 1091356--3/31/2008--SEAENA_INC. |
| 1292026--3/31/2009--Odimo_INC |
| 1292026--3/31/2010--Odimo_INC |
| 351017--3/27/2008--AUTOINFO_INC |
| 351017--3/23/2009--AUTOINFO_INC |
| 1011733--4/15/2009--TRIMOL_GROUP_INC |
| 1021917--10/13/2009--ASPEON_INC |
| 1063530--4/15/2009--POWER_3_MEDICAL_PRODUCTS_INC |
| 1371128--3/25/2008--BioSolar_Inc |
| 1450552--12/29/2010--Dafoe_Corp. |
| 1419260--1/6/2010--Andina_Group_Inc. |
| 75439--3/31/2009--CytoCore_Inc |
| 1080001--1/15/2009--NEWTECH_RESOURCES_LTD |
| 919567--9/22/2006--RENAISSANCE_CAPITAL_GROWTH_&_INCOME_FUND_III_INC |
| 1099132--4/9/2010--MANHATTAN_SCIENTIFICS_INC |
| 1099132--5/6/2009--MANHATTAN_SCIENTIFICS_INC |
| 778438--3/6/2006--BERRY_PETROLEUM_CO |
| 746834--3/13/2006--NGAS_Resources_Inc |
| 919567--3/27/2008--RENAISSANCE_CAPITAL_GROWTH_&_INCOME_FUND_III_INC |
| 95366--1/13/2009--SUNAIR_SERVICES_CORP |
| 1104904--10/16/2006--XINHUA_CHINA_LTD |
| 1101298--4/9/2008--ASP_VENTURES_CORP |
| 1140657--3/26/2008--HUNTINGTON_PREFERRED_CAPITAL_INC |
| 1265840--11/12/2009--AMERICAS_WIND_ENERGY_CORP |
|